Gyre Therapeutics (NASDAQ:GYRE) Trading 7.9% Higher – What’s Next?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s stock price traded up 7.9% during mid-day trading on Thursday . The stock traded as high as $6.04 and last traded at $6.14. 24,311 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 90,412 shares. The stock had previously closed at $5.69.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Zacks Research cut Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, March 16th. Wall Street Zen cut Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings cut Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, Gyre Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Gyre Therapeutics Stock Performance

The stock has a market capitalization of $610.32 million, a PE ratio of -69.88 and a beta of 1.90. The stock has a 50-day moving average price of $6.98 and a two-hundred day moving average price of $7.47.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings data on Thursday, March 12th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%. The company had revenue of $37.20 million for the quarter, compared to analysts’ expectations of $36.30 million. As a group, equities analysts predict that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Weiguo Ye sold 12,820 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $6.15, for a total value of $78,843.00. Following the transaction, the chief operating officer directly owned 700,000 shares of the company’s stock, valued at approximately $4,305,000. The trade was a 1.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ying Luo sold 10,136 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total value of $81,493.44. Following the completion of the transaction, the chief executive officer directly owned 2,565,226 shares in the company, valued at approximately $20,624,417.04. This represents a 0.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 32,535 shares of company stock worth $219,580. 9.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its holdings in Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after purchasing an additional 1,402 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in Gyre Therapeutics by 9.5% in the 3rd quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock worth $163,000 after purchasing an additional 1,900 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Gyre Therapeutics by 4.7% in the 1st quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company’s stock worth $301,000 after purchasing an additional 1,941 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after purchasing an additional 3,244 shares in the last quarter. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.